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Idd Loci Synergize to Prolong Islet Allograft Survival
Induced by Costimulation Blockade in NOD Mice
Julie Mangada,1,2 Todd Pearson,2 Michael A. Brehm,3 Linda S. Wicker,4 Laurence B. Peterson,5
Leonard D. Shultz,6 David V. Serreze,6 Aldo A. Rossini,2 and Dale L. Greiner2
OBJECTIVE—NOD mice model human type 1 diabetes and are
used to investigate tolerance induction protocols for islet trans-
plantation in a setting of autoimmunity. However, costimulation
blockade–based tolerance protocols have failed in prolonging
islet allograft survival in NOD mice.
RESEARCH DESIGN AND METHODS—To investigate the
underlying mechanisms, we studied the ability of costimulation
blockade to prolong islet allograft survival in congenic NOD mice
bearing insulin-dependent diabetes (Idd) loci that reduce the
frequency of diabetes.
RESULTS—The frequency of diabetes is reduced in NOD.B6
Idd3 mice and is virtually absent in NOD.B6/B10 Idd3 Idd5
mice. Islet allograft survival in NOD.B6 Idd3 mice treated with
costimulation blockade is prolonged compared with NOD
mice, and in NOD.B6/B10 Idd3 Idd5, mice islet allograft
survival is similar to that achieved in C57BL/6 mice. Con-
versely, some Idd loci were not beneficial for the induction of
transplantation tolerance. Alloreactive CD8 T-cell depletion in
(NOD  CBA)F1 mice treated with costimulation blockade
was impaired compared with similarly treated (C57BL/6.H2g7 
CBA)F1 mice. Injection of exogenous interleukin (IL)-2 into NOD
mice treated with costimulation prolonged islet allograft sur-
vival. NOD.B6 Idd3 mice treated with costimulation blockade
deleted alloreactive CD8 T-cells and exhibited prolonged islet
allograft survival.
CONCLUSIONS—Il2 is the Idd3 diabetes susceptibility gene
and can influence the outcome of T-cell deletion and islet
allograft survival in mice treated with costimulation blockade.
These data suggest that Idd loci can facilitate induction of
transplantation tolerance by costimulation blockade and that
IL-2/Idd3 is a critical component in this process. Diabetes 58:
165–173, 2009
The NOD mouse is a model of type 1–like autoim-mune diabetes and is used to study costimula-tion blockade–based transplantation tolerancewithin the context of autoimmunity (1–4). How-
ever, costimulation blockade protocols fail in NOD mice.
To investigate further the cellular and genetic control of
costimulation blockade–induced transplantation toler-
ance, we used NOD Idd congenic mice that have small
introgressed regions of genetic intervals derived from
diabetes-resistant C57 stocks. These mice exhibit varying
degrees of protection from autoantibodies, insulitis, and
diabetes (5). Using Idd congenic NOD mice, we have
observed that islet allograft survival is improved by the
addition of the diabetes-protective Idd3 locus (6,7).
Idd3 modulates infiltration of autoreactive lymphocytes
into the islets (8), and there is compelling evidence that
Idd3 is the interleukin (IL)-2 gene (9). In vivo stimulated
NOD T-cells produce twofold less IL-2 mRNA than cells
from NOD congenic mice having protective alleles at Idd3
(9,10). Neutralizing antibodies to IL-2 lead to accelerated
disease in NOD mice (11), and targeted genetic disruption
of IL-2 accelerates type 1–like autoimmune diabetes (9).
Treatment with exogenous IL-2 inhibits diabetes develop-
ment in NOD mice and improves T regulatory (Treg)
function (12). IL-2 is also known to have a nonredundant
role in CD8 T-cell activation–induced cell death via the
CD95 (Fas) pathway (13), is required for the development
of self-tolerance (14), and is essential for the induction of
allograft tolerance by costimulation blockade (15). How-
ever, IL-2 is a double-edged sword, since administration of
IL-2 in vivo can either enhance or depress a cytotoxic T
lymphocyte (CTL) response (16).
In this study, we show that costimulation blockade fails
to delete alloreactive CD8 T-cells in NOD mice. Genetic
replacement of IL-2 in NOD.B6 Idd3 mice enhances allo-
reactive CD8 T-cell deletion and improves islet allograft
survival. Finally, we show that Idd3 synergizes with genes
within the Idd5 interval, leading to permanent islet allo-
graft survival in a majority of NOD.B6/B10 Idd3 Idd5 mice
treated with costimulation blockade.
RESEARCH DESIGN AND METHODS
C3H/He (H2k) mice were obtained from the National Cancer Institute (Fred-
erick, MD), The Jackson Laboratory (Bar Harbor, ME), or Taconic Farms
(Germantown, NY). NOD-Prkdcscid (NOD-scid) mice were obtained from The
Jackson Laboratory. C57BL/6 (H2b), NOD/Mrk-TacfBR, NOD.B6 Idd3R450
(Taconic line 1098), NOD.CZECH Idd3 (Taconic line 1590), NOD.B6 Idd3R450
B10 Idd5R444 (Taconic lines 1591 and 6109), NOD.B6 Idd3R450  B10
Idd5R467 (Taconic line 1573), NOD.B10 Idd5R444 (Taconic line 1094),
NOD.B6 Idd3 Idd10 Idd18R323 (Taconic line 1538), and NOD.B6 Idd10
Idd18(R2) (Taconic lines 1101 and 7754) were obtained from Taconic Farms.
Because the experimental data using the NOD.B6 Idd3R450 (Taconic line
1098) and NOD.CZECH Idd3 (Taconic line 1590) congenic variants of Idd3
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were comparable (9), these groups have been combined for presentation and
are referred to in the text as NOD.B6 Idd3 mice. A schematic of the congenic
intervals on mouse chromosomes is shown in Fig. 1. C57BL/6.NODc17 (H2g7,
C57BL/6.H2g7) mice were developed by Edward Wakeland, University of
Texas Southwestern Medical Center, Dallas, Texas (17). (KB5 CBA  C57BL/
6.H2g7) F1 mice and (KB5 CBA  NOD) F1 mice were generated by a single
intercross of the appropriate parental strains and were bred in our facility. The
KB5 TCR transgene is expressed in CBA (H2k) mice by CD8 T-cells and is
specific for native H2-Kb (18).
Animals were certified to be free of infectious pathogens, housed in
microisolator cages within a specific pathogen-free facility, and given auto-
claved food and acidified water ad libitum. All animal use was in accordance
with the guidelines of the Animal Care and Use Committee of the University
of Massachusetts Medical School and recommendations in the Guide for the
Care and Use of Laboratory Animals (Institute of Laboratory Animal Re-
sources, National Research Council, National Academy of Sciences, 1996).
Generation of KB5 synchimeras. KB5 synchimeric mice were generated
using a previously described procedure (18). Briefly, (CBA/J  NOD)F1 mice
carrying a single copy of a B6-like allele of the IL-2 gene (19) and (CBA/J 
C57BL/6.H2g7)F1 mice carrying two copies of a B6 or B6-like IL-2 gene were
irradiated with 400 cGy from a 137Cs source (Gammacell 40; Atomic Energy of
Canada, Ottawa, ON, Canada) and given a single intravenous injection of 0.5
106 (KB5 CBA  NOD)F1 or (KB5 CBA  C57BL/6.H2g7)F1 transgenic bone
marrow cells, respectively. Mice were entered into experiments 8–12 weeks
after bone marrow transplantation.
Antibodies and flow cytometry. The KB5-specific clonotypic Desire` (DES)
antibody was the gift of Dr. John Iacomini (Harvard Medical School, Boston,
MA). Fluorescein isothiocyanate–conjugated anti-mouse IgG2a (clone R19-15)
and PerCept-conjugated anti-mouse CD8 monoclonal antibodies (mAbs)
(clone 53-6.7) were obtained from BD PharMingen (San Diego, CA). Isotype
control mAbs including rat PerCP-conjugated IgG2a  (clone R35-95) and
mouse IgG2a  anti-TNP (clone G155-178) were purchased from BD Phar-
Mingen.
Two-color flow cytometry analyses of lymph node and spleen cells were
performed (20). Briefly, cells were incubated with anti-FcRIII/II mAb (clone
2.4G2) to eliminate nonspecific Fc binding. Cells were washed, incubated with
anti-DES antibody, washed, and incubated with fluorescein isothiocyanate–
conjugated anti-mouse IgG2a mAb plus a mixture of conjugated mAbs. Whole
blood was processed using fluorescence-activated cell sorter lysing solution
(Becton Dickinson, Sunnyvale, CA). Labeled cells were washed, fixed with 1%
paraformaldehyde-PBS, and analyzed using a FACScan instrument (Becton
Dickinson). Lymphoid cells were gated according to their light-scattering
properties, and 30–50  103 events were acquired for each analysis.
MR1 hamster anti-mouse CD154 mAb was produced as tissue culture
supernatant and purified by affinity chromatography (National Cell Culture
Center, Minneapolis, MN) (18). Contaminating endotoxin was uniformly 10
units/mg of mAb.
Histology. Kidneys bearing islet grafts were fixed in Bouin’s solution.
Paraffin-embedded sections were prepared and stained with hematoxylin and
eosin. Additional sections were stained for the presence of insulin and
glucagon.
Tolerance induction and allograft transplantation. Diabetes was induced
in 6- to 8-week-old male mice by a single intraperitoneal injection of
streptozotocin (150 mg/kg) (6). Animals were tested for glycosuria (test strips,
Glucosin; Bayer, Elkhart, IN) twice weekly. Diabetes was confirmed by
documenting plasma glucose concentration 250 mg/dl (Accu-Chek Active,
Roche Diagnostics, Indianapolis, IN.). Mice hyperglycemic for at least 1 week
were used in the experiments. Chemically diabetic mice were treated with our
standard costimulation blockade protocol consisting of a single C3H/He
donor-specific transfusion (DST) of 107 spleen cells injected intravenously on
day 7 and with anti-CD154 mAb (0.5 mg/dose) on days 7, 4, 0, and 4
relative to transplantation on day 0 (6).
Islets isolated from C3H/He donors by collagenase digestion followed by
density gradient separation were transplanted (20 islets/g body weight) into
the renal subcapsular space of chemically diabetic recipients (21,22). Animals
were tested for glycosuria twice weekly, and allograft rejection was defined as
recurrent hyperglycemia (250 mg/dl) on at least 2 consecutive days. Unilat-
eral nephrectomy of the graft-bearing kidney was performed on all islet
allograft recipients that were normoglycemic at the conclusion of an experi-
ment to confirm allograft function.
(KB5 CBA  NOD)F1 or (KB5 CBA  C57BL/6.H2g7)F1 synchimeric mice
were treated with C57BL/6 DST and anti-CD154 mAb (18).
Injection of IL-2 during costimulation blockade. Recombinant murine
IL-2 (0.8 	g, R&D systems, Minneapolis, MN) was injected intraperitoneally on
days 7, 6, 5, 4, and 3 relative to analysis of KB5 DES CD8 T-cells
or transplantation on day 0. Concurrently, costimulation blockade consisting
of DST on day 7 and injections of anti-CD154 mAb on days 7, 4, 0, and
4 were performed relative to transplantation on day 0.
In vivo cytotoxicity assay. The in vivo cytotoxicity assay was performed as
previously described (23). Briefly, 6- to 8-week-old male NOD, C57BL/6, or
NOD.B6 Idd3mice were treated on day7 with DST and on days7 and4 with
anti-CD154 mAb relative to depletion of natural killer (NK) cells on day 8 by
injection of 1 mg anti-CD122 mAb (24). On day 0 (the normal day of islet
transplantation), carboxyfluorescein diacetate succinimidyl ester–labeled spleno-
cytes were adoptively transferred intravenously into naive recipient mice or into
the indicated recipient mice. Spleens from recipient mice were harvested 20 h
later, and the survival of each transferred population was assessed by flow
cytometry. Specific lysis was calculated as described (23).
In vitro NK cell cytotoxicity assay. The in vitro NK cell cytotoxicity assay
was performed as previously described (25) using spleen cells from mice
injected 24 h previously with 100 	g polyinosinic:polycytidylic (poly I:C) as
effectors and 51Cr-labeled YAC-1 cells as targets. In some cohorts, NK cells
were depleted by injection of 1 mg anti-CD122 mAb 1 day before poly I:C
administration. Percent specific lysis was calculated as follows: % specific
lysis 
 [(experimental lysis – spontaneous lysis)/(maximal lysis – spontane-
ous lysis)]  100.
Statistical analysis. Median duration of allograft survival is presented. Graft
survival among groups was compared using the method of Kaplan and Meier.
The equality of allograft survival distributions for animals in different treat-
ment groups was tested using the log rank statistic. P values 0.05 were
considered statistically significant. Data are presented as the mean  1 SD.
Comparisons of two means used Student’s t test with separate variance
estimates. Comparisons of three or more means used one-way ANOVA and the
least significant difference procedure for a posteriori contrasts.
RESULTS
Islet allograft rejection in chemically diabetic male
NOD mice is not due to islet autoimmunity. Islet
allograft survival in chemically diabetic male NOD mice
treated with our costimulation blockade protocol is rela-
tively short (6). However, in those experiments, islet graft
rejection could have resulted from islet autoimmunity or
the failure to induce allograft tolerance. To investigate
this, chemically diabetic NOD mice were transplanted
with syngeneic NOD-scid islets. As reported previously
(26), we observed through 150 days after islet transplan-
tation that all mice (5/5) remained normoglycemic. Analy-
sis of the islet-bearing kidney revealed an insulin-
producing islet graft present at the time of necropsy with
only a small amount of leukocytic infiltrate. These data
suggest that islet allograft rejection in our model system
results from failure to induce tolerance and not to the
development of islet autoimmunity.
Islet allograft survival in NOD.B6 Idd10 Idd18 and
NOD.B6 Idd3 Idd10 Idd18 congenic mice after treat-
ment with DST and anti-CD154 mAb. Islet allograft
survival is prolonged in NOD mice bearing the diabetes-
resistant Idd3 congenic interval (6). However, Idd3 is only
partially protective but, when combined with certain other
Idd loci, almost completely protects NOD mice from
diabetes (Fig. 1). We hypothesized that combinations of
Idd loci that are strongly protective against diabetes would
enhance islet allograft survival. NOD mice congenic for
the Idd10 Idd18 intervals have reduced incidence of
diabetes (27,28) and, when combined with Idd3, have a
very low frequency of diabetes (8,27,29).
Confirming our previous report (6), islet allograft sur-
vival in NOD mice treated with costimulation blockade is
short (median survival time [MST] was 74 days), whereas
permanent islet allograft survival (MST 240 days) is
observed in the majority of similarly treated C57BL/6 mice
(Fig. 2A). We also confirmed that NOD mice bearing the
Idd3 congenic interval exhibit islet allograft survival that
is prolonged (MST 
 140 days, [6]) compared with NOD
mice but significantly shorter than that achieved in
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C57BL/6 mice (Fig. 2B). Surprisingly, we observed that
NOD Idd10 Idd18 congenic mice exhibited shorter islet
allograft survival (MST 
 63 days) than that achieved in
NOD mice (Fig. 2). Combination of the Idd10 Idd18
genetic intervals with the beneficial effects of Idd3 did not
alter islet allograft survival compared with that achieved in
NOD.B6 Idd3 congenic mice (NS, Fig. 2A and B).
Protective Idd5 and Idd3 alleles synergize to prolong
islet allograft survival in chemically diabetic NOD
mice treated with DST and anti-CD154 mAb. We next
studied the effects of Idd5 alone or in combination with
Idd3. NOD mice bearing the Idd5 disease-resistant loci are
partially protected from diabetes (30,31), and the addition
of Idd3 protective alleles results in nearly complete dis-
ease suppression (31,32).
NOD.B10 Idd5 congenic mice treated with DST and
anti-CD154 did not exhibit prolonged islet allograft sur-
vival (MST 
 96 days) compared with that achieved in
NOD mice (NS, Fig. 2B) and was significantly shorter than
that achieved in NOD.B6 Idd3 congenic mice (P  0.005,
Fig. 2B). These data, combined with the NOD.B6 Idd10
Idd18 results, demonstrate that enhancement of islet
allograft survival by Idd loci does not strictly correlate
with the extent to which they suppress diabetes.
Strikingly, NOD mice bearing the diabetes-protective Idd3
and Idd5 congenic intervals exhibited prolonged islet allo-
graft survival (MST 250 days), which was similar to that
achieved in C57BL/6 mice (NS) and significantly greater than
that achieved in NOD (P  0.005) or NOD.B10 Idd5 mice
(P 0.01, Fig. 2B). In long-term surviving islet allografts, we
routinely observed minimal to no mononuclear infiltration.
Islet allograft survival in Idd3 congenic NOD mice
bearing different Idd5 subregions treated with
costimulation blockade. The Idd5 interval congenic
strain used in this study contains at least three diabetes-
resistant loci: Idd5.1, Idd5.2, and Idd5.3 (30,31). To begin
to identify the congenic Idd5 interval that synergizes with
Idd3 to prolong islet allograft survival in NOD mice treated
with costimulation blockade, we tested two newly devel-
oped NOD congenic lines that carry the B6-derived Idd3
congenic interval as well as the B10-derived Idd5.1 or
Idd5.1 plus Idd5.3 intervals (Fig. 1).
NOD.B6 Idd3 B10 Idd5.1 congenic mice treated with
costimulation blockade exhibited islet allograft survival
shorter (MST 
 69 days) than that achieved in C57BL/6
mice (P  0.0001) and not different from that achieved in
NOD mice (NS, Fig. 3). Islet allograft survival was also not
enhanced in NOD.B6 Idd3 B10 Idd5.1 Idd5.3 mice (MST

13 days) over that achieved in NOD.B6 Idd3 B10 Idd5.1
congenic mice (NS, Fig. 3). These data suggest that
expression of Idd5.2 encoding a nonfunctional protein is
important for the beneficial effects of Idd5 in conjunction
with Idd3 and that all three subregions are needed—or
that Idd5.2 alone or in combo with Idd5.1 or Idd5.3 is
beneficial. Interestingly, we observed that a proportion of
animals maintained long-term graft function.
Failure of costimulation blockade treatment to de-
lete alloreactive CD8 T-cells in (NOD  KB5)F1
synchimeric mice is reversed by IL-2. Idd3-mediated
diabetes susceptibility in NOD mice is caused by an IL-2
allele that is transcribed at lower levels than variants
contributing to disease resistance (9) and is important for
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FIG. 2. Life table analysis of islet allograft survival in chemically diabetic congenic NOD mice. The 6- to 8-week-old male mice were treated with
a DST plus anti-CD154 mAb. DST (107 C3H/He spleen cells) was given on day 7, and anti-CD154 mAb (0.5 mg/dose) was given on days 7, 4,
0, and 4 relative to transplantation with C3H/He islets on day 0. Vertical bars indicate mice removed from the study with intact grafts or alive
with intact grafts at the conclusion of the period of observation. Comparative P values of islet allograft survival in the groups are shown. A: Idd10
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Idd LOCI IN NOD MICE
168 DIABETES, VOL. 58, JANUARY 2009
tolerance induction (33). Therefore, we hypothesized that
a deficiency in IL-2 production in NOD mice impairs host
alloreactive CD8 T-cell deletion.
To test this hypothesis, we modified our synchimera
model system based on KB5 TCR transgenic alloreactive
CD8 T-cells (18). KB5 CBA mice were mated with NOD
mice or with C57BL/6.H2g7 mice bearing the NOD major
histocompatibility complex and were used to generate
synchimeric mice (18). Synchimeric mice were treated
with C57BL/6 DST and anti-CD154, and the circulating
levels of KB5 transgenic alloreactive CD8 T-cells were
analyzed on day 0. Two groups of synchimeric mice were
also given five daily injections of mouse rIL-2 beginning on
the day of DST.
(KB5 CBA C57BL/6.H2g7)F1 synchimeric mice treated
with costimulation blockade exhibited marked deletion of
their alloreactive CD8 T-cells (63  30%, Fig. 4). Similar
results were seen in the (KB5 CBA  C57BL/6.H2g7)F1
synchimeric mice that received exogenous IL-2 in addition
to the DST and anti-CD154 (70  6%). In contrast, (KB5
CBA  NOD)F1 mice exhibited significantly less deletion
of their alloreactive CD8 T-cell population (34  24%),
which was restored by IL-2 treatment (63 21%) to a level
similar to that observed in (KB5 CBA  C57BL/6.H2g7)F1
mice (Fig. 4).
IL-2 improves islet allograft survival in NOD mice
treated with costimulation blockade. We next hypoth-
esized that increased deletion of alloreactive CD8 T-cells
in (KB5 CBA  NOD)F1 mice treated with costimulation
blockade plus IL-2 would lead to a difference in islet
allograft survival. To test this, chemically diabetic NOD
mice were treated with costimulation blockade and trans-
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levels of KB5 transgenic CD8 T-cells on day 0 as described in RESEARCH DESIGN AND METHODS. P values are indicated by horizontal bars.
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planted with C3H/He islets with or without peri-transplant
injection of IL-2.
As expected (6), islet allograft survival in NOD mice
treated with costimulation blockade was short (MST 
 46
days, Fig. 5). In contrast, NOD mice treated with costimu-
lation blockade and IL-2 exhibited slightly but significantly
prolonged islet allograft survival (MST 
 83 days), al-
though all islet allografts were eventually rejected (Fig. 5).
NOD.B6 Idd3 congenic mice exhibit a restored ability
to delete alloreactive CD8 T-cells after costimulation
blockade. Having observed that the Idd3 locus improved
islet allograft survival (Fig. 5) and that exogenous admin-
istration of IL-2 improved alloreactive CD8 T-cell deletion
in our synchimeric model system (Fig. 4), we next tested
directly our hypothesis that restoration of a normal IL-2
gene by the Idd3 locus in NOD mice would restore the
ability of costimulation blockade to delete alloreactive
CD8 T-cells. To directly identify alloreactive CD8 T-cell
function in NOD.B6 Idd3 mice, we used an in vivo cyto-
toxicity assay (23). In NK cell–depleted mice, all in vivo
cytotoxic activity is due to alloreactive CD8 T-cells (34).
We first confirmed (24) that the anti-CD122 antibody
would delete all NK cell cytotoxic activity in NOD mice
(Fig. 6A). As expected, NK-depleted C57BL/6 mice treated
with costimulation blockade exhibited low in vivo cyto-
toxicity, whereas alloreactive CD8 T-cell activity in NOD
mice was high (Fig. 6B). In NK-depleted NOD.B6 Idd3
mice, in vivo cytotoxicity was significantly lower than
that observed in NOD mice and was comparable to that
observed in C57BL/6 mice (Fig. 6B). In all three strains,
priming NK cell– depleted mice with a DST alone in-
duced strong in vivo alloreactive CD8 T-cell cytotoxicity
(Fig. 6B).
DISCUSSION
We have confirmed in this article that islet allograft
survival in NOD.B6 Idd3 mice treated with costimulation
blockade is prolonged compared with NOD mice (1). We
now document that some but not all Idd resistance loci
synergize with Idd3 to enhance islet allograft survival. We
further show that a major tolerance defect in NOD mice is
the resistance of alloreactive CD8 T-cells to deletion by
costimulation blockade, a defect that can be reversed by
addition of the Idd3 gene or by administration of exoge-
nous IL-2.
Disease-resistant alleles at the Idd10 Idd18 region pro-
vide moderate protection against diabetes (45–55%)
(27,28,35), and together, the Idd3 Idd10 and Idd18 protec-
tive alleles confer almost complete resistance (8,27,29).
We hypothesized that NOD.B6 Idd10 Idd18 mice and
NOD.B6 Idd3 Idd10 Idd18 mice would demonstrate a
stepwise improvement in costimulation blockade–induced
islet allograft survival. Surprisingly, islet allograft survival
in NOD.B6 Idd10 Idd18 mice was not increased over that
achieved in NOD mice and did not increase over that
achieved with Idd3 alone.
Genes located within the Idd10 and Idd18 intervals
include Ptpn22, which is orthologous to PTPN22, a human
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gene that is associated with the development of diabetes
and other autoimmune diseases (28,36). The disease-
associated allele of human PTPN22 is a gain-of-function
variant that in vitro suppresses TCR signaling in response
to TCR/CD28 ligation to a greater extent than the more
common allele (37). The functional outcome of TCR
signaling in the PTPN22 gain-of-function variant reduces
expression of IL-2. Studies that altered the allelic status of
the Ptpn22 region in NOD congenic mice have demon-
strated that the B6-derived interval confers susceptibility
to type 1–like autoimmune diabetes (L.S.W., L.B.P., unpub-
lished data), therefore providing a potential explanation
for the inability of the B6-derived Idd10 Idd18 region to
increase islet allograft survival.
Given the surprising results seen with the NOD.B6 Idd3
Idd10 Idd18 islet allograft studies, we next determined
whether a synergistic effect could be found between Idd3
and Idd5. NOD.B10 Idd5 mice have a lower frequency of
diabetes than NOD mice, and when combined with resis-
tance alleles at Idd3, the frequency of spontaneous diabe-
tes is 2% (30,32). Importantly, islet allograft survival in
NOD.B6 Idd3 Idd5 mice was increased to levels achieved
in C57BL/6 mice.
The Idd5 congenic strain used in our study contains at
least three diabetes resistance genes, termed Idd5.1,
Idd5.2, and Idd5.3 (30). The Idd5.1 gene is most likely a
variant of Ctla4, with the diabetes-prone NOD allele
producing less of the ligand-independent CTLA-4
(liCTLA-4) molecule than the resistant B10 allele (38).
CTLA-4 is critical for the induction of tolerance using
costimulation blockade (39). Slc11a1 (formerly known as
Nramp1) is likely to be the causal Idd5.2 gene (40).
Interestingly, the B10 diabetes-resistant Nramp1 allele
encodes a nonfunctional protein (41). However, Idd5.2/
Nramp1 is not required for the decreased diabetes fre-
quency in NOD.B6 Idd3 B10 Idd5 mice, although the
B10-derived Idd5.2 region is required to maintain the
reduced insulitis present in NOD.B6 Idd3 B10 Idd5 mice
(31). In addition, the non–NOD-derived Idd5.1/Ctla4 and
Idd3 resistance alleles did not increase protection from
diabetes compared with Idd3 alone (31). These results are
consistent with our islet allograft survival data. The syn-
ergy observed between Idd5 and Idd3 that results in
nearly complete protection from diabetes and insulitis and
increases islet allograft survival to a C57BL/6-like fre-
quency is dependent on the B10-derived Idd5.2 region,
either alone or in combination with the other Idd5 loci. To
extend this observation, additional congenic strain combi-
nations would have to be developed and tested: Idd3/
Idd5.3, Idd3/Idd5.2, and Idd3/Idd5.2/Idd5.3.
Idd3, which is partially protective of diabetes, signifi-
cantly improves islet allograft survival in the NOD mouse,
with the strongest effect seen in the NOD.B6 Idd3 B10
Idd5 congenic strain. The Idd3 effect likely results from
differential expression of IL-2 that modulates CD4CD25
Treg cell function in NOD mice (9). IL-2 is also required for
the development of self-tolerance and for costimulation
blockade–induced allograft tolerance (10,15).
Based on the NOD.B6 Idd3 congenic data, we hypothe-
sized that the inability to induce tolerance in NOD mice is
due to a failure to efficiently delete host alloreactive CD8
T-cells and that injection of exogenous IL-2 would correct
this defect. As expected, (KB5 CBA  C57BL/6.H2g7)F1
synchimeric mice treated with costimulation blockade
showed a marked deletion of alloreactive CD8 T-cells
compared with (KB5 CBA  NOD)F1 synchimeric mice.
When (KB5 CBA  NOD)F1 synchimeric mice were
treated with exogenous IL-2, alloreactive CD8 T-cell
deletion was significantly improved. These data suggest
that NOD mice fail to efficiently delete alloreactive CD8
T-cells because of insufficient IL-2 production.
To extend this finding, we observed that islet allograft
survival in NOD mice treated with costimulation blockade
plus IL-2 was slightly longer than in those receiving
costimulation blockade alone, likely through enhancement
of alloreactive CD8 T-cell apoptosis (16). This interpreta-
tion has previously been proposed based on the observa-
tion that coadministration of rapamycin plus IL-2 prevents
spontaneous and recurrent autoimmunity in NOD mice
through the ability of rapamycin to inhibit IL-2 T-cell
proliferation but not IL-2–induced apoptosis (42). The fact
that graft survival isn’t as prolonged as that achieved in
NOD.B6 Idd3 mice may be due to the transient adminis-
tration of IL-2 and its short half-life, whereas the increased
IL-2 achieved in NOD.B6 Idd3 mice is present throughout
the animal’s life. Alternatively, we had previously docu-
mented in CD8-deficient NOD and (NOD  C57BL/6)F1
mice that CD8 T-cells are not solely responsible for the
failure to induce prolonged allograft survival after co-
stimulation blockade (7), implicating a role for Il2/Idd3 in
other transplantation tolerance pathways, consistent with
the known role of Idd3 in Treg function in NOD mice (9).
These data suggest that impaired production of IL-2 in
NOD mice is a barrier to costimulation blockade–induced
tolerance. IL-2 is indispensable for supporting the in vivo
growth, survival, and function of naturally occurring Tregs
(11,43–46), and because of their corrected Idd3 haplotype,
NOD.B6 Idd3 mice have CD4CD25 Tregs with enhanced
regulatory activity (9).
In summary, we have shown that the resistance to
costimulation blockade–induced tolerance to islet allo-
grafts in NOD mice is in part due to the failure to efficiently
delete alloreactive CD8 T-cells. Genetically, this can be
overcome by the introgression of a normal Idd3 (i.e., Il2)
gene that synergizes with one or more protective subre-
gions within Idd5 to promote allograft tolerance. Specula-
tively, we propose that the B6 allele of Idd3 might also
contribute to the apoptosis of islet-specific CD8 cells in
spontaneous diabetes. Because SNP polymorphisms in the
IL-2 receptor have been associated with a genetic predis-
position for type 1 diabetes in humans (47), these data
suggest that regulation of IL-2 may be important not only
for diabetes but also for islet transplantation in type 1
diabetic individuals.
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